Trial · NCT03562130
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
NCT03562130, Phase 4, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients. Trials, record NCT03562130. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03562130
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
- NCT number
- NCT03562130
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 25 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Short Bowel Syndrome
- Interventions
- Teduglutide
- First posted
- 2018-06-19
- Last updated
- 2025-09-11
- Other registries' IDs
- eudract:2017-001405-32
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Decrease in parenteral nutrition: Parenteral Nutrition/Resting Energy Expenditure (PN/REE) | At week 24 | Evaluate the efficacy of Revestive® treatment |
| Secondary | Ostomy output defined as stool balance testing, urine output and plasma citrulline | up to week 48 | Evaluate the impact of Revestive on ostomy flow |
| Secondary | Change in days per week of Parenteral Nutrition (PN) | up to week 48 | Quantify the impact of Revestive on the number of perfusion in a week |
| Secondary | Change in number of stool per day | up to week 48 | to evaluate the impact of Revestive on diarrhea |
| Secondary | Change in stools consistency (Bristol stool chart) | up to week 48 | to evaluate the impact of Revestive on diarrhea |
| Secondary | Ingesta (calorimetric measure) | Every 4 weeks up to week 48 | to evaluate the impact of Revestive on Intestinal absorption |
| Secondary | Stool weight/24h | Every 4 weeks up to week 48 | to evaluate the impact of Revestive on Intestinal absorption |
| Secondary | Percentage of lipid in stool | Every 4 weeks up to week 48 | to evaluate the impact of Revestive on Intestinal absorption |
| Secondary | Percentage of nitrogen in stool | Every 4 weeks up to week 48 | to evaluate the impact of Revestive on Intestinal absorption |
| Secondary | Percentage of carbohydrate in stool | Every 4 weeks up to week 48 | to evaluate the impact of Revestive on Intestinal absorption |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37270289 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03562130
GET https://conductscience.org/api/trials/v1/NCT03562130/registered